OA10880A - Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs - Google Patents

Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs Download PDF

Info

Publication number: OA10880A
Authority: OA; OAPI
Prior art keywords: tpgs; vitamin; compound; water soluble; hiv protease
Prior art date: 1996-03-22

Application number

OA9800171A

Other languages

English (en)

Inventor

Arup K Roy

Lioyd Gary Tillman

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-22

Filing date

1998-09-18

Publication date

2001-10-11

1996-03-26 Priority claimed from GBGB9606372.2A external-priority patent/GB9606372D0/en

1998-09-18 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2001-10-11 Publication of OA10880A publication Critical patent/OA10880A/en

Links

239000004030 hiv protease inhibitor Substances 0.000 title claims abstract description 27
239000000203 mixture Substances 0.000 title claims description 49
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims description 28
AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 title claims description 27
229940122440 HIV protease inhibitor Drugs 0.000 title claims description 18
150000001875 compounds Chemical class 0.000 title description 48
229940088594 vitamin Drugs 0.000 title description 4
229930003231 vitamin Natural products 0.000 title description 4
239000011782 vitamin Substances 0.000 title description 4
235000013343 vitamin Nutrition 0.000 title description 4
150000003722 vitamin derivatives Chemical class 0.000 title description 4
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 23
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 23
229930003799 tocopherol Natural products 0.000 claims abstract description 22
239000011732 tocopherol Substances 0.000 claims abstract description 22
235000010384 tocopherol Nutrition 0.000 claims abstract description 21
229960001295 tocopherol Drugs 0.000 claims abstract description 21
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
-1 tetrahydro-3-furanyl ester Chemical class 0.000 claims abstract description 10
KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims abstract description 5
UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims abstract description 5
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 5
KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims abstract description 5
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims abstract description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 51
238000009472 formulation Methods 0.000 claims description 42
239000003125 aqueous solvent Substances 0.000 claims description 9
229920001223 polyethylene glycol Polymers 0.000 claims description 8
239000002202 Polyethylene glycol Substances 0.000 claims description 7
238000000034 method Methods 0.000 claims description 7
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
239000004698 Polyethylene Substances 0.000 claims description 2
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 2
229920000573 polyethylene Polymers 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 abstract description 7
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract description 3
238000013160 medical therapy Methods 0.000 abstract description 3
239000000243 solution Substances 0.000 description 25
239000002775 capsule Substances 0.000 description 18
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 16
239000003814 drug Substances 0.000 description 14
229940068918 polyethylene glycol 400 Drugs 0.000 description 14
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 13
229940079593 drug Drugs 0.000 description 13
108010010369 HIV Protease Proteins 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
239000002904 solvent Substances 0.000 description 7
241000700159 Rattus Species 0.000 description 6
239000007903 gelatin capsule Substances 0.000 description 6
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
208000030507 AIDS Diseases 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 4
239000003995 emulsifying agent Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
206010001513 AIDS related complex Diseases 0.000 description 3
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
229930105110 Cyclosporin A Natural products 0.000 description 3
108010036949 Cyclosporine Proteins 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
241000725303 Human immunodeficiency virus Species 0.000 description 3
230000037396 body weight Effects 0.000 description 3
229960001265 ciclosporin Drugs 0.000 description 3
239000006184 cosolvent Substances 0.000 description 3
229930182912 cyclosporin Natural products 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
230000009969 flowable effect Effects 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
208000031886 HIV Infections Diseases 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 2
ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 2
230000002411 adverse Effects 0.000 description 2
229940087168 alpha tocopherol Drugs 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
229960001936 indinavir Drugs 0.000 description 2
CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000012669 liquid formulation Substances 0.000 description 2
239000000178 monomer Substances 0.000 description 2
NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
229960000311 ritonavir Drugs 0.000 description 2
NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
239000000725 suspension Substances 0.000 description 2
AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
229960000984 tocofersolan Drugs 0.000 description 2
238000011282 treatment Methods 0.000 description 2
235000004835 α-tocopherol Nutrition 0.000 description 2
239000002076 α-tocopherol Substances 0.000 description 2
XEDONBRPTABQFB-UHFFFAOYSA-N 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(O)=C1C=O XEDONBRPTABQFB-UHFFFAOYSA-N 0.000 description 1
WKVDSZYIGHLONN-RRKCRQDMSA-N 5-chloro-1-[(2r,4s,5r)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](F)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Cl)=C1 WKVDSZYIGHLONN-RRKCRQDMSA-N 0.000 description 1
WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
JARNKPQDFXUJTE-UHFFFAOYSA-N [3-hydroxy-5-[[3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamic acid Chemical compound C=1C=CC=CC=1CC(NC(O)=O)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 JARNKPQDFXUJTE-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000619 acesulfame-K Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
239000008122 artificial sweetener Substances 0.000 description 1
235000021311 artificial sweeteners Nutrition 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
229960002656 didanosine Drugs 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
150000002303 glucose derivatives Chemical class 0.000 description 1
UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
229960001627 lamivudine Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
229960000884 nelfinavir Drugs 0.000 description 1
QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
229960000689 nevirapine Drugs 0.000 description 1
229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
WTTIBCHOELPGFK-LBPRGKRZSA-N r82150 Chemical compound C1N(CC=C(C)C)[C@@H](C)CN2C(=S)NC3=CC=CC1=C32 WTTIBCHOELPGFK-LBPRGKRZSA-N 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229960001852 saquinavir Drugs 0.000 description 1
QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
235000020374 simple syrup Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
229960001203 stavudine Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
235000019149 tocopherols Nutrition 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
229950009795 tucaresol Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1
229960000523 zalcitabine Drugs 0.000 description 1
QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Engineering & Computer Science (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

OA9800171A 1996-03-22 1998-09-18 Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs OA10880A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US1389396P	1996-03-22	1996-03-22
GBGB9606372.2A GB9606372D0 (en)	1996-03-26	1996-03-26	Pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
OA10880A true OA10880A (en)	2001-10-11

Family

ID=26308992

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9800171A OA10880A (en)	1996-03-22	1998-09-18	Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs

Country Status (12)

Country	Link
JP (1)	JP3117726B2 (id)
AR (1)	AR006345A1 (id)
BG (1)	BG64457B1 (id)
CO (1)	CO4790151A1 (id)
HU (1)	HU228026B1 (id)
ID (1)	ID16781A (id)
IL (1)	IL126185A (id)
MY (1)	MY126358A (id)
OA (1)	OA10880A (id)
PL (1)	PL187919B1 (id)
TW (1)	TW455491B (id)
WO (1)	WO1997035587A1 (id)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2001523221A (ja) *	1996-09-01	2001-11-20	ファーモスコーポレイション	親油性物質の促進された生物学的利用能のための固形共沈物
WO1998057648A1 (en) *	1997-06-16	1998-12-23	Vertex Pharmaceuticals Incorporated	Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US5891845A (en) *	1997-11-21	1999-04-06	Fuisz Technologies Ltd.	Drug delivery systems utilizing liquid crystal structures
ES2140329B1 (es) *	1997-12-04	2000-10-16	Univ Granada	Utilizacion de acido maslinico como inhibidor de proteasas para el tratamiento de la enfermedad causada por los virus de la inmunodeficiencia adquirida.
GB9812189D0 (en) *	1998-06-05	1998-08-05	Glaxo Group Ltd	Methods and compositions for increasing penetration of HIV protease inhibitors
CA2432527A1 (en) *	2000-12-22	2002-07-04	Takeda Chemical Industries, Ltd.	Medicinal compositions for oral use
WO2004050068A1 (en)	2002-11-29	2004-06-17	Janssen Pharmaceutica N.V.	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US7423004B2 (en)	2003-01-31	2008-09-09	Smithkline Beecham Corporation	Solid dispersion compositions
WO2006036614A2 (en) *	2004-09-24	2006-04-06	Boehringer Ingelheim Pharmaceuticals, Inc.	A new class of surfactant-like materials comprising vitamin e tpgs and a water soluble polymer
EP1793806A2 (en) *	2004-09-30	2007-06-13	Eastman Chemical Company	Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
EP1880715A1 (en)	2006-07-19	2008-01-23	Abbott GmbH & Co. KG	Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
SA109300195B1 (ar)	2008-03-28	2013-04-20	Astrazeneca Ab	تركيبة صيدلانية جديدة مضادة للسرطان
ITRM20120331A1 (it)	2012-07-12	2014-01-13	Guidotti & C Spa Labor	Composizioni pediatriche orali liquide contenenti nepadutant.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992016501A1 (en) *	1991-03-20	1992-10-01	Vertex Pharmaceuticals Incorporated	Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease
ATE163926T1 (de) *	1991-11-08	1998-03-15	Merck & Co Inc	Hiv-protease-inhibitoren verwendbar in der aids- behandlung
IS2334B (is) *	1992-09-08	2008-02-15	Vertex Pharmaceuticals Inc., (A Massachusetts Corporation)	Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
WO1994013629A1 (en) *	1992-12-11	1994-06-23	Vertex Pharmaceuticals Incorporated	Mannitol derivatives and their use as inhibitors of aspartyl protease
US5484926A (en) *	1993-10-07	1996-01-16	Agouron Pharmaceuticals, Inc.	HIV protease inhibitors
CA2170020C (en) *	1992-12-29	2005-08-02	Dale J. Kempf	Retroviral protease inhibiting compounds
WO1994015608A1 (en) *	1993-01-15	1994-07-21	Agouron Pharmaceuticals, Inc.	Hiv protease inhibitors
WO1995012583A1 (en) *	1993-11-05	1995-05-11	Merck & Co., Inc.	New quinazolines as inhibitors of hiv reverse transcriptase
IL111584A0 (en) *	1993-11-18	1995-01-24	Merck & Co Inc	Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
JP3000564B2 (ja) *	1993-12-15	2000-01-17	メルクエンドカンパニーインコーポレーテッド	Ｈｉｖプロテアーゼ阻害剤
WO1995024385A1 (en) *	1994-03-07	1995-09-14	Vertex Pharmaceuticals Incorporated	Sulphonamide derivatives as aspartyl protease inhibitors
GB9409778D0 (en) *	1994-05-16	1994-07-06	Dumex Ltd As	Compositions
US5527829A (en) *	1994-05-23	1996-06-18	Agouron Pharmaceuticals, Inc.	HIV protease inhibitors
JPH11505257A (ja) *	1995-05-19	1999-05-18	アボツト・ラボラトリーズ	親油性薬物の自己乳化性製剤

1997
- 1997-03-20 MY MYPI97001186A patent/MY126358A/en unknown
- 1997-03-21 IL IL12618597A patent/IL126185A/xx not_active IP Right Cessation
- 1997-03-21 WO PCT/EP1997/001438 patent/WO1997035587A1/en not_active Ceased
- 1997-03-21 PL PL32891697A patent/PL187919B1/pl unknown
- 1997-03-21 HU HU9901887A patent/HU228026B1/hu unknown
- 1997-03-21 CO CO97015457A patent/CO4790151A1/es unknown
- 1997-03-21 JP JP09534017A patent/JP3117726B2/ja not_active Expired - Lifetime
- 1997-03-21 TW TW086103607A patent/TW455491B/zh not_active IP Right Cessation
- 1997-03-21 ID IDP970927A patent/ID16781A/id unknown
- 1997-03-21 AR ARP970101146A patent/AR006345A1/es active IP Right Grant
1998
- 1998-09-18 OA OA9800171A patent/OA10880A/en unknown
- 1998-10-12 BG BG102838A patent/BG64457B1/bg unknown

Also Published As

Publication number	Publication date
PL328916A1 (en)	1999-03-01
MY126358A (en)	2006-09-29
JP3117726B2 (ja)	2000-12-18
WO1997035587A1 (en)	1997-10-02
HU228026B1 (en)	2012-08-28
HUP9901887A2 (hu)	1999-12-28
JP2000500504A (ja)	2000-01-18
BG64457B1 (bg)	2005-03-31
AR006345A1 (es)	1999-08-25
IL126185A0 (en)	1999-05-09
ID16781A (id)	1997-11-13
IL126185A (en)	2003-05-29
CO4790151A1 (es)	1999-05-31
HUP9901887A3 (en)	2000-02-28
PL187919B1 (pl)	2004-11-30
BG102838A (en)	1999-09-30
TW455491B (en)	2001-09-21

Publication	Publication Date	Title
US5200192A (en)	1993-04-06	Instant oral-release capsule containing nifedipine
US20110020440A1 (en)	2011-01-27	Stable solutions of sparingly soluble actives
US6730679B1 (en)	2004-05-04	Pharmaceutical formulations
OA10880A (en)	2001-10-11	Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
US6551615B1 (en)	2003-04-22	Dexibuprofen-containing soft gelatin capsules and process for preparing the same
AU2002356421A1 (en)	2003-07-03	Dexibuprofen-containing soft gelatin capsules and process for preparing the same
RU2363462C2 (ru)	2009-08-10	Фармацевтическая композиция, содержащая 5-метил-2-(2′-хлор-6′-фторанилин)фенилуксусную кислоту
AP1150A (en)	2003-03-14	Compositions comprising an HIV protease inhibitor such as Vx 478 and a water soluble vitamin E compound such as vitamin E-TPGS.
KR100472581B1 (ko)	2005-06-16	Vx478과같은hiv프로테아제억제제및비타민e-tpgs와같은수용성비타민e화합물을포함하는조성물
US7632853B2 (en)	2009-12-15	Soluble, stable and concentrated pharmaceutical composition compromising ritonavir and process for preparing thereof
HK1016896B (en)	2003-07-11	Compositions comprising vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
AU2010338249B2 (en)	2016-03-31	Oral liquid pharmaceutical composition of nifedipine
US20060141028A1 (en)	2006-06-29	Cyclosporin formulations
UA67723C2 (en)	2004-07-15	Pharmaceutical formulations for peroral administration and method for its preparation
US20060217320A1 (en)	2006-09-28	Soft gel formulations for saquinavir